What is Camzyos?
Camzyos is an oral prescription medication used to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This condition, specifically for those in New York Heart Association (NYHA) Class II and III, involves a thickening of the heart muscle, which can obstruct blood flow and cause symptoms like shortness of breath, chest pain, and fatigue, especially during exertion. Camzyos represents a targeted therapy designed to improve functional capacity and reduce these debilitating symptoms, offering a significant advancement for patients managing this chronic disease.
How does Camzyos work?
Camzyos works by directly targeting the underlying cause of oHCM at the muscular level of the heart. Its active ingredient, mavacamten, is a cardiac myosin inhibitor. In oHCM, the heart muscle contracts too forcefully due to an excess of connections (cross-bridges) between myosin and actin proteins. Camzyos blocks these extra connections, reducing the muscle’s hypercontractility. This action helps the heart to relax properly between beats, reduces the obstruction of blood flow, and eases the overall workload on the heart, thereby improving symptoms and physical function.
Who is Camzyos for?
Camzyos is intended for adults who have been diagnosed with symptomatic NYHA Class II or III obstructive hypertrophic cardiomyopathy. NYHA Class II refers to patients with slight limitation of physical activity, while Class III refers to those with marked limitation. This medication is for individuals looking to improve their ability to be active and to lessen symptoms such as shortness of breath, dizziness, and fatigue. Because of its specific mechanism and potential side effects, patient selection is crucial and requires a thorough medical evaluation by a cardiologist.
Dosage and administration
Camzyos is administered as an oral capsule, taken once per day, and can be consumed with or without food. The specific dosage is determined by your doctor based on your individual health status, response to the medication, and results from regular heart monitoring. It is critical that patients do not change their dose or stop taking Camzyos without consulting their healthcare provider. Treatment requires regular monitoring, including echocardiograms, to ensure the dose is both safe and effective for you.
Side effects
The most common side effects of Camzyos can include dizziness and fainting (syncope). The most serious potential side effect is a risk of heart failure, which occurs if the medication reduces the heart’s pumping action too much (systolic dysfunction). To manage this risk, your doctor will monitor your heart function with echocardiograms before and during your treatment. If you experience new or worsening shortness of breath, chest pain, fatigue, or swelling in your legs, contact your doctor immediately. You can review a more complete list of side effects in the corresponding section below.
Why buy from IsraelPharm?
IsraelPharm offers a reliable and affordable way to access essential medications like Camzyos. By sourcing drugs directly from a network of regulated international pharmacies, we can provide significant savings without compromising on quality or safety. Our streamlined ordering process, dedicated customer service team, and commitment to authentic, brand-name pharmaceuticals make us a trusted choice for patients worldwide. When you choose IsraelPharm, you choose a partner in your health journey, ensuring you receive the treatment you need at a price you can afford.
Serious Side Effects:
Camzyos carries a risk of reducing the heart’s pumping function, which can lead to heart failure. Your doctor will monitor for this. Seek immediate medical attention if you experience:
- New or worsening shortness of breath
- Chest pain
- Significant fatigue
- Swelling in the ankles, feet, or legs (edema)
- Rapid weight gain
Common Side Effects:
- Dizziness
- Fainting (syncope)
This is not a complete list of all possible side effects. Consult your doctor for medical advice about adverse effects.
Camzyos (mavacamten) is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (oHCM).
It is prescribed to achieve the following:
- Improvement in functional capacity
- Reduction in symptoms such as shortness of breath